טוען...
Intravitreal Bevacizumab for Neovascular Glaucoma
PURPOSE: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone. DESIGN: retrospective, consecutive case series. METHODS: Charts of patients with NVG from retinal is...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc.
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2981382/ https://ncbi.nlm.nih.gov/pubmed/19857107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jop.2009.0036 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|